exagamglogene autotemcel

targets

all catalysts(0)

nothing on the calendar yet

News(8)

• Aura, Schrödinger trim workforces
  Follow along as BioSpace tracks job cuts and restructuring initiatives.
  biospace · 1d ago
• Biotech startup funding gap widens despite rebound in VC investment
  Though funding totals represented the highest first-half sum since the start of 2022, industry watchers are concerned that small startups are being left behind.
  biopharma_dive · 1mo ago
• Vertex's sickle cell therapy approved for kids; United Therapeutics buys startup
  🧬 Vertex’s sickle cell gene therapy approved for kids: Casgevy may now be used to treat either sickle cell disease with recurrent vaso-occlusive crises or transfusion-dependent β-thalassemia patie…
  endpoints · 1mo ago
• FDA Approves First Gene Therapy for Young Children with Sickle Cell Disease
  The U.S. Food and Drug Administration today issued a supplemental approval for Casgevy (exagamglogene autotemcel) for patients aged 2 years and older with either sickle cell disease (SCD) with recu…
  fda_press · 1mo ago
• BridgeBio gets funding for drug launch; United buys into cell therapy
  Elsewhere, Otsuka’s kidney drug hit the goal of a confirmatory trial and Vertex’s CRISPR sickle cell drug secured expanded approval.
  biopharma_dive · 1mo ago
• Vertex earnings get muted investor response
  While overall revenue fell just shy of Wall Street forecasts, sales of the gene editing medicine Casgevy and pain drug Journavx missed analyst estimates by double-digit percentages.
  biopharma_dive · 3mo ago
• STAT+: Pharmalittle: We’re reading about a Lilly deal, an Intellia CRISPR rare-disease treatment, and more
  Intellia disclosed that a single dose of its gene editing treatment dramatically reduced swelling attacks in patients with hereditary angioedema
  stat · 3mo ago
• STAT+: Intellia says CRISPR-based treatment for rare disease reduced swelling attacks in pivotal trial
  With good results from Intellia, the CRISPR field faces the question: How attractive will the one-and-done approach be to patients and doctors?
  stat · 3mo ago